Tokyo, July 4, 2006 (JCN) - Asahi Kasei Pharma and CoTherix have entered into a licensing agreement for oral and inhaled formulations of fasudil, a rho-kinase inhibitor developed by Asahi Kasei Pharma. Under the agreement announced June 29, Asahi Kasei Parma will license CoTherix of California to develop and sell fasudil in North America and Europe. CoTherix plans to introduce the agent for the treatments of angina (oral formulation) and pulmonary hypertension (both oral and inhaled formulations).
